Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BTK inhibitor 13
CAS :<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Formule :C29H26FN5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :511.55FGFR-IN-4
CAS :<p>FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.</p>Formule :C24H21N7O2Couleur et forme :SolidMasse moléculaire :439.47ALK/EGFR-IN-2
CAS :<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Formule :C27H34ClN7O3SCouleur et forme :SolidMasse moléculaire :572.12HPK1-IN-2 dihydrochloride
CAS :<p>HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].</p>Formule :C19H22Cl2N6OSCouleur et forme :SolidMasse moléculaire :453.39FC 11
CAS :<p>FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.</p>Formule :C41H42F3N13O9SCouleur et forme :SolidMasse moléculaire :949.91HER2-IN-5
CAS :<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formule :C27H33N7O3Couleur et forme :SolidMasse moléculaire :503.6Nazartinib S-enantiomer
CAS :<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Formule :C26H31ClN6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :495.02HDAC-IN-50
CAS :<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Formule :C31H41N7O4Couleur et forme :SolidMasse moléculaire :575.7HDAC-IN-63
CAS :<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Formule :C25H26Cl2N6O3Couleur et forme :SolidMasse moléculaire :529.42EGFR-IN-32
CAS :<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formule :C31H34N6O3Couleur et forme :SolidMasse moléculaire :538.64BTK inhibitor 20
CAS :<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Formule :C37H42N8O4Couleur et forme :SolidMasse moléculaire :662.78Irpagratinib
CAS :<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Formule :C28H32F2N6O5Degré de pureté :99.08% - 99.38%Couleur et forme :SolidMasse moléculaire :570.59BTK-IN-18
CAS :<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Formule :C20H22Cl2N6OCouleur et forme :SolidMasse moléculaire :433.33BTK-IN-11
CAS :<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Formule :C26H22ClN5O3Couleur et forme :SolidMasse moléculaire :487.94Infigratinib-Boc
CAS :<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Formule :C29H35Cl2N7O5Couleur et forme :SolidMasse moléculaire :632.54BPR1J-340
CAS :<p>BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.</p>Formule :C29H34N8O3Couleur et forme :SolidMasse moléculaire :542.63JGK-068S
CAS :<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formule :C22H23BrFN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :488.35AT-9283 L-lactate
CAS :<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Formule :C22H29N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :471.52EVT801
CAS :<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Formule :C19H21N5O3Degré de pureté :97.4%Couleur et forme :SolidMasse moléculaire :367.4BCR-ABL-IN-4
CAS :<p>BCR-ABL-IN-4: Anticancer BCR-ABL inhibitor; stops K562 cells (IC50: 0.67 nM), targets T315I Ba/F3 cells (IC50: 16 nM).</p>Formule :C27H24ClF2N5O4Couleur et forme :SolidMasse moléculaire :555.96PF-06459988
CAS :<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formule :C19H22ClN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :431.88Nezulcitinib
CAS :<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Formule :C30H37N7O2Couleur et forme :SolidMasse moléculaire :527.66FLT3/ITD-IN-5
CAS :<p>FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.</p>Formule :C23H25N7O2Couleur et forme :SolidMasse moléculaire :431.49TIE-2/VEGFR-2 kinase-IN-4
CAS :<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Formule :C26H17F4N5O4Couleur et forme :SolidMasse moléculaire :539.44CCT365623 hydrochloride
CAS :<p>CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.</p>Formule :C18H18ClNO4S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :443.99CT-721
CAS :<p>CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.</p>Formule :C30H29ClN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :525.04(Z)-RG-13022
CAS :<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formule :C16H14N2O2Couleur et forme :SolidMasse moléculaire :266.29HIF-2α-IN-1
CAS :<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Formule :C16H8F5NO4SDegré de pureté :97.99%Couleur et forme :SolidMasse moléculaire :405.3YS-363
CAS :<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formule :C30H30N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :494.5810Z-Hymenialdisine
CAS :<p>Pan kinase inhibitor</p>Formule :C11H10BrN5O2Degré de pureté :98%Couleur et forme :Light Yellow SolidMasse moléculaire :324.13Henatinib
CAS :<p>Henatinib: orally active multi-kinase inhibitor targeting VEGFR-2, c-kit, PDGFR with antitumor effects.</p>Formule :C25H29FN4O4Couleur et forme :SolidMasse moléculaire :468.52FLT3-IN-14
CAS :<p>FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.</p>Formule :C25H24N6O2SCouleur et forme :SolidMasse moléculaire :472.56Sulfatinib
CAS :<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Formule :C24H28N6O3SDegré de pureté :99.21% - >99.99%Couleur et forme :SolidMasse moléculaire :480.58EGFR-IN-33
CAS :<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97JAK-IN-26
CAS :<p>JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency in</p>Formule :C22H24N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :420.46Larixol
CAS :<p>Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for</p>Formule :C20H34O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :306.48Ruxolitinib sulfate
CAS :<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Formule :C17H20N6O4SCouleur et forme :SolidMasse moléculaire :404.45TG 100572 Hydrochloride
CAS :<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Formule :C26H27Cl2N5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.43JAK-IN-4
CAS :<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Formule :C18H21N4Na2O6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :466.341Risvodetinib
CAS :<p>Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.</p>Formule :C33H34N8O2Couleur et forme :SolidMasse moléculaire :574.68ALK/ROS1-IN-1
CAS :<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Formule :C30H35F3N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :584.63EGFR kinase inhibitor 1
CAS :<p>Potent EGFR blocker; acts on WT, L858R/T790M (IC50: 1.7 nM), less on T790M/C797S; stalls cell cycle, induces apoptosis, deters metastasis.</p>Formule :C30H31N7O2Couleur et forme :SolidMasse moléculaire :521.61BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Formule :C26H23N7O2Couleur et forme :SolidMasse moléculaire :465.51FGFR-IN-8
CAS :<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Formule :C27H31Cl2N9O2Couleur et forme :SolidMasse moléculaire :584.5CHMFL-FLT3-122
CAS :<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Formule :C26H29N7O2Degré de pureté :99.63%Couleur et forme :SolidMasse moléculaire :471.55MS 154
CAS :<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Formule :C46H54ClFN8O8Couleur et forme :SolidMasse moléculaire :901.42FGFR-IN-2
CAS :<p>FGFR-IN-2 (compound 1) is a potent inhibitor of FGFR, acting on FGFR1 (IC50: 7.3 nM), FGFR2 (IC50: 4.3 nM), FGFR3 (IC50: 7.6 nM) and FGFR4 (IC50: 11 nM).</p>Formule :C25H30N6O2Couleur et forme :SolidMasse moléculaire :446.54GSK2646264
CAS :<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Formule :C24H26N2O2Couleur et forme :SolidMasse moléculaire :374.48EGFR-IN-30
CAS :<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formule :C28H33BrN7O2PCouleur et forme :SolidMasse moléculaire :610.49SG3-179
CAS :<p>SG3-179 is a BET inhibitor.</p>Formule :C28H35ClFN7O3SCouleur et forme :SolidMasse moléculaire :604.14CP-547632 TFA
CAS :<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Formule :C22H25BrF5N5O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :646.43EGFR-IN-36
CAS :<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97TAK-659
CAS :<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Formule :C17H21FN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :344.39Famitinib malate
CAS :<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Formule :C27H33FN4O7Couleur et forme :SolidMasse moléculaire :544.57BMS-599626 Hydrochloride
CAS :<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formule :C27H28ClFN8O3Degré de pureté :99.98%Couleur et forme :SolidMasse moléculaire :567.01Upadacitinib tartrate
CAS :<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formule :C21H33F3N6O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :602.521Roslin 2 bromide
CAS :<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Formule :C13H19BrN4Degré de pureté :99.34%Couleur et forme :SolidMasse moléculaire :311.22PF-303
CAS :<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Formule :C22H21ClN6O2Couleur et forme :SolidMasse moléculaire :436.89JNJ-17029259
CAS :<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Formule :C26H30N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.56JAK-IN-24
CAS :<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formule :C20H25N5O2Couleur et forme :SolidMasse moléculaire :367.44EGFR-IN-29
CAS :<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formule :C36H46BrN8O2PCouleur et forme :SolidMasse moléculaire :733.68Brolucizumab
CAS :<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Degré de pureté :95%Couleur et forme :LiquidSNIPER(TACC3)-11
CAS :<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Formule :C51H66N10O7S2Couleur et forme :SolidMasse moléculaire :995.26Atiprimod dimaleate
CAS :<p>Atiprimod Dimaleate is a JAK2 inhibitor.</p>Formule :C30H52N2O8Couleur et forme :SolidMasse moléculaire :568.74MET kinase-IN-3
CAS :<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formule :C25H16ClF2N5O2Couleur et forme :SolidMasse moléculaire :491.88TCJL37
CAS :<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formule :C17H11ClF2N4O2Couleur et forme :SolidMasse moléculaire :376.74Simotinib
CAS :<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formule :C25H26ClFN4O4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :500.95ALK/EGFR-IN-1
CAS :<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Formule :C27H34ClN7O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :572.12SD 1008
CAS :<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Formule :C18H19NO5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :329.35PAT-505
CAS :<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formule :C23H18ClF2N3O2SDegré de pureté :98.84%Couleur et forme :SolidMasse moléculaire :473.92Itacnosertib (hydrocholide)
CAS :<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formule :C26H29ClN8OCouleur et forme :SolidMasse moléculaire :505.01DZD1516
CAS :<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formule :C28H27F2N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :547.56EGFR-IN-71
CAS :<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formule :C16H9ClIN3Couleur et forme :SolidMasse moléculaire :405.62UNC4203
CAS :<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Formule :C30H44N6OCouleur et forme :SolidMasse moléculaire :504.71PI3K/VEGFR2-IN-1
CAS :<p>PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.</p>Formule :C17H14ClN3OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :343.83KB SRC 4
CAS :<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Formule :C32H23ClN8Degré de pureté :98.83% - 99.34%Couleur et forme :SolidMasse moléculaire :555.03MTP
CAS :<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Formule :C29H23F3N4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :516.51ALK/EGFR-IN-3
CAS :<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Formule :C27H34ClN7O3SCouleur et forme :SolidMasse moléculaire :572.12HDAC/JAK/BRD4-IN-1
CAS :<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Formule :C24H28N6O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.52BPIQ-I
CAS :<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formule :C16H12BrN5Couleur et forme :SolidMasse moléculaire :354.2FM-479
CAS :<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formule :C25H26N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.523EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Formule :C32H28BrF3N6O4SCouleur et forme :SolidMasse moléculaire :729.57Pivanex
CAS :<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Formule :C10H18O4Degré de pureté :≥98%Couleur et forme :SolidMasse moléculaire :202.25FLT3/ITD-IN-4
CAS :<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Formule :C25H22N4O5Couleur et forme :SolidMasse moléculaire :458.47T338C Src-IN-1
CAS :<p>T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).</p>Formule :C17H20N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :372.44JAK-IN-1
CAS :<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formule :C20H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.44UNC5293
CAS :<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Formule :C30H42N6O2Couleur et forme :SolidMasse moléculaire :518.69ALK-IN-6
CAS :<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Formule :C26H29ClD3N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :533.1BGB-102
CAS :<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formule :C22H25BrN4O2Degré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :457.36Lepzacitinib
CAS :<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formule :C18H21N5O3Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :355.39TIE-2/VEGFR-2 kinase-IN-3
CAS :<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Formule :C23H17F4N5O3SCouleur et forme :SolidMasse moléculaire :519.47JAK-IN-25
CAS :<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formule :C19H17N5O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :379.37Tubulin/JAK2-IN-1
CAS :<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formule :C22H20N6O3Couleur et forme :SolidMasse moléculaire :416.43Tyk2-IN-9
CAS :<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formule :C20H17N9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :383.41(Rac)-PF-06250112
CAS :<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Formule :C22H20F2N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :438.43JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formule :C33H38F2N6O8Couleur et forme :SolidMasse moléculaire :684.69EGFR-IN-87
CAS :<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61KER047
CAS :<p>ALK2-IN-4, a highly effective ALK2 inhibitor.</p>Formule :C26H30FN7ODegré de pureté :98.49% - >99.99%Couleur et forme :SolidMasse moléculaire :475.56IN-1130
CAS :<p>IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).</p>Formule :C25H20N6ODegré de pureté :99.79%Couleur et forme :SolidMasse moléculaire :420.47Zongertinib
CAS :<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Formule :C29H29N9O2Degré de pureté :98.24%Couleur et forme :SolidMasse moléculaire :535.6
